Bio-Rad Laboratories launches the EQAS Blood Gas Program
HERCULES, CA – October 25, 2012 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products today announced the release of its External Quality Assurance Service (EQAS) Blood Gas Program.
The EQAS Blood Gas Program is an external quality assessment (EQA) program that is designed for the quantitative measurement of blood gas, electrolytes, glucose, lactate, and magnesium.
The way in which the program works is one of 12 samples are tested each month throughout a one-year cycle. Test results are then presented as a monthly report that is either posted online or sent directly to participants. The report includes informative statistical analyses and valuable peer group comparisons. A comprehensive End-of-Cycle Report provides an overall assessment of bias over the entire cycle. Registered EQAS participants may access their reports online at QCNet™ (www.qcnet.com).
As a provider of proficiency testing (PT) programs, Bio-Rad offers fully accredited PT/EQA programs in chemistry (serum and urine), immunoassay, therapeutic drugs, hemoglobin, and hematology.
For more information, please contact your local Bio-Rad representative or read more about the EQAS Blood Gas Program on our website at www.QCNet.com.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
Azita Mokhtari, Product Manager
Bio-Rad Laboratories, Inc.